

Eric S Leifer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/903891/publications.pdf>

Version: 2024-02-01

13
papers

2,465
citations

932766

10
h-index

1199166

12
g-index

13
all docs

13
docs citations

13
times ranked

3158
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	13.9	778
2	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	13.9	712
3	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	3.8	386
4	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1703.	3.8	186
5	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood, 2021, 137, 420-428.	0.6	119
6	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	3.8	89
7	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	3.0	74
8	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. JACC: Heart Failure, 2019, 7, 158-168.	1.9	65
9	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. European Journal of Heart Failure, 2019, 21, 770-778.	2.9	36
10	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplantation and Cellular Therapy, 2022, 28, 109.e1-109.e8.	0.6	12
11	Joint testing of overall and simple effects for the two-by-two factorial trial design. Clinical Trials, 2021, 18, 521-528.	0.7	5
12	The influence of comorbidities on achieving an N-terminal pro-B-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC Heart Failure, 2021, , .	1.4	3
13	Discussion of A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III by Andrew G. Chapple and Peter F. Thall. Biometrics, 2019, 75, 382-384.	0.8	0